Systemic Treatment Options for Non-Small Cell Lung Cancer
Christine Bestvina, MD, presents her treatment strategy for a 62-year-old female with NSCLC, bone and liver metastases, and an EGFR exon 20 insertion; the panel then assesses clinical data, including the MARIPOSA trial, to guide their treatment decisions.
EP: 1.Patient Case 1: A 62-Year-Old Female with NSCLC
Now Viewing
EP: 2.Systemic Treatment Options for Non-Small Cell Lung Cancer
EP: 3.Counseling Patients and Caregivers on NSCLC Treatment Toxicities
EP: 4.Patient Case 2: A 45-Year-Old Man with NSCLC Stage IV with Bone and Liver Metastases
EP: 5.Patient Case 3: A 34-Year-Old Non-Smoker with Stage IIIA NSCLC
EP: 6.Patient Case 4: 50-Year-Old Woman Non-Smoker with Pleural Metastases
EP: 7.Molecular Testing: Key Takeaways on Next Generation Sequencing in NSCLC
EP: 8.Closing Thoughts on the Future of NSCLC
EP: 9.Amivantamab Is Preferred First-Line Pick in EGFR Exon 20 NSCLC
Recent Videos
